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Abstract 
Background: Type 2 diabetes (T2D) and colon cancer (CC) are numbered among the most common diseases in the 
world. The decreased activity of natural killer (NK) cells previously revealed in both mentioned pathological states may 
be correlated with impaired expression of GLUT4 as the major insulin‑dependent glucose transporter in these cells.
Methods: The aim of this study was to evaluate GLUT4 expression and NK cells number in subjects with T2D and/or 
CC in comparison with control group. We evaluated 78 individuals divided into four groups: (1) patients with CC and 
T2DM, (2) patients with CC, (3) patients with T2DM (4) healthy control. GLUT4 expression on the surface of NK cells 
was measured using flow cytometry and phenotyping of NK cell was performed by immunofluorescent method.
Results: Subjects with diabetes had the highest GLUT4 expression (21.35 ± 7.2 %) in comparison with other groups 
(P < 0.01). The mean values of GLUT4 expression in group with CC and in patients with both T2D and CC were similar 
(1.4 ± 0.4 % vs 1.5 ± 1.0 %; respectively). These values were significantly lower than in control group (12.6 ± 2.9 %; 
P < 0.01). In patients with T2D and CC the number of NK cells (20.15 ± 6.6 %) was significantly higher than in other 
groups, i.e. in group with T2D (14.08 ± 5.7 %), in group with CC (9.21 ± 3.6 %) and in control group (9.48 ± 4.7 %), 
respectively (P < 0.01).
Conclusions: It seems that there is a need to pay more attention to the high incidence of colon cancer among 
patients with type 2 diabetes. Decreased GLUT4 expression observed on NK cells in patients with colon cancer may 
be responsible for dysfunction of these cells and the higher carcinogenic risk in type 2 diabetic subjects.
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Background
Type 2 diabetes and colon cancer are currently numbered 
among the most common diseases in the world. In both 
diseases, there is a rise in the number of new cases each 
year and prognosis for upcoming years is unfortunately 
very worrying. Poland had the highest death rate from 
colon cancer for both genders in the year 2013—25  % 
higher in men and 13  % higher in women when com-
pared to the rest of the European Union [1, 2].
Colon cancer is more common in diabetic patients—
type 2 diabetes increases the risk of colon cancer about 
40–60  % [3–6]. It is certainly a complex relationship 
which is connected with a sedentary lifestyle, obesity, 
improper diet, food portions with high glycemic index, 
altered concentration of endogenous hormones, as well 
as the presence of hyperinsulinemia, hyperglycemia and 
insulin resistance that promote tumor growth [7–9].
Glucose is a major energetic substrate for human cells 
but cellular membranes are impenetrable for glucose, so 
the cellular transport is possible due to special proteins. 
There are two types of sugar transporters depending on 
their use of energy for glucose transport: Na+-dependent 
glucose co-transporters (SGLT), which require energy for 
transport, and facilitative Na+-independent sugar trans-
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gradient to move it through membranes, so their action 
is based on the diffusion [10].
GLUT proteins are a family of particular isoforms 
which differ from each other in the amino-acidic 
sequences, but the general outline of their construction 
is similar—about 50 % of the protein mass is constituted 
by a highly conservative intracellular domain, the seg-
ments of which create 12 a-helices formed into a hydro-
philic channel allowing the sugar transport to take place. 
Other domains are less conservative—extracellular and 
cytoplasmatic, which contains the N-terminus fragment, 
C-terminus fragment and the large loop linking segments 
6 and 7. Class I of glucotransporters includes isoforms—
GLUT1–4 [11–13]. Expression of GLUT isoforms is spe-
cific for cells and tissues and modified by hormonal and 
environmental factors [14]. In previous publications, the 
author has proved the presence of GLUT-1, GLUT-3, 
GLUT-4 glucotransporters on the surface of peripheral 
blood lymphocytes.
In physiological conditions, a quantitative coordination 
between the activity of molecular intracellular glucose 
transport system and glucose plasma metabolism exists 
but in T2D this coordination becomes impaired. Can-
cer cells are well known to display an enhanced glucose 
uptake and consumption, and in these cells glucose trans-
porters are dysregulated and they incorporate higher 
amounts of glucose than normal cells because they need 
large amounts of energy for their extremely intensive 
growth and proliferation. Special glucose transporter 
proteins (GLUTs) are necessary for that process [15]. 
Many cancer cell lines exhibit an excessive expression 
of GLUTs [16]. GLUT4 plays a crucial role in glucose 
metabolism and represents 90 % of glucose transporters 
[17]. GLUT4 displays an interesting connection with can-
cer because this transporter is transcriptionally repressed 
by p53 [18], a tumor suppressor protein important for 
cell cycle control and apoptosis, processes that are altered 
usually in cancer.
NK (natural killer) cells that constitute from 5 to 19 % 
of the peripheral blood lymphocytes are first line of 
defense against tumor cells. They are characterized by 
the ability to destroy target cells spontaneously, with-
out prior immunization [19]. It was observed, that the 
lower NK cell activity is associated with a higher risk of 
developing cancer [20]. The NK cell number and activity 
in cancer patients decreases with increasing severity of 
the cancer [21]. Altered NK cell activity also was shown 
in obese healthy humans. Laue et al. have demonstrated 
that NK cells in obese subjects had functional deficits 
and altered responses after in vitro leptin challenge [22]. 
Similar disturbances in the functioning of NK cell activity 
were observed in patients with type 2 diabetes. Disadvan-
tageous alterations of NK cells may lead to impairment 
in their cytotoxic activity, which can be involved in the 
increased carcinogenic risk [23], and may contribute in 
an increased risk of cancer in these patients [24].
Identification of mechanisms underlying the occur-
rence of colon cancer in patients with type 2 diabetes is 
important due to the high and steadily increasing inci-
dence of both mentioned diseases in population. So, 
the aim of this study was to evaluate GLUT4 expression 
and NK cells number in patients with colon cancer and 
coexisting type 2 diabetes in comparison with diabetic 
subjects without cancer, subjects with colon cancer and 
normal glucose tolerance, as well as with healthy control 
group.
Methods
This study was performed in Department of Internal 
Diseases, Diabetology and Endocrinology in coopera-
tion with Department of General and Vascular Surgery 
and department of Nuclear Medicine of Warsaw Medical 
University. Recruitment and qualification of patients was 
based on general internal examination, with particular 
emphasis on family interviews and biochemical tests. All 
people participating in the study were informed in detail 
about the conducted experiments and the safety prin-
ciples before they were allowed to give their consent to 
participate in the study. Qualifying tests were conducted 
under the protocol approved by the Commission of Bio-
ethics at the Medical University of Warsaw (No. 189/2009 
of 20 October 2009).
Patients were divided into four groups: (1) patients with 
CC in stage T1-4N0M0 and T2DM treated with diet and/
or oral antidiabetic agents—(DC), (2) patients with CC in 
stage T1-4N0M0 with normal glucose tolerance—(C), (3) 
patients with T2DM treated with diet and/or oral anti-
diabetic agents without CC and with a negative history of 
cancer—(D), and (4) healthy individuals who constituted 
the control group—(control). We excluded patients with 
renal insufficiency (serum creatinine >1.3  mg/dl), liver 
diseases, symptomatic heart failure, diabetic complica-
tions, using diabetogenic drugs (systemic corticosteroids, 
oral contraceptives, thiazide diuretics), abusing drugs or 
alcohol.
The diagnosis of CC was established on the basis of 
medical history as well as physical and endoscopic exam-
ination. Computed tomography of the abdomen was per-
formed to determine the staging of cancer (TNM). The 
study included patients with clinical diagnosis of CC 
without lymph node metastases and distant metasta-
ses (T1-4N0M0). The operation was conducted within a 
period of up to 14 days after establishing the clinical diag-
nosis. Histopathological results verified the clinical diag-
nosis—in all patients the presence of adenocarcinomas 
was registered. Due to finding metastasis in mesenteric 
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lymph nodes, four patients were excluded from the C 
group and four patients from the DC group.
Finally, the analysis included a total of 78 subjects: 19 
patients with CC (T1-4N0M0) and T2DM: DC group, 19 
patients with CC (T1-4N0M0) and normal glucose toler-
ance: C group, 20 patients with T2DM: D group, and 20 
healthy control group.
Biochemical tests
We measured fasting plasma glucose (FPG)—with 
enzymatic method using BIOSEN 5040 analyzer (EKF-
Diagnostic GmbH, Germany), glycated hemoglobin 
(HbA1c)—with high-performance liquid chromatog-
raphy (HPLC) method using Variant analyzer (Bio-Rad 
Laboratories Inc, USA), insulin—with radioimmunoassay 
IMMULITE 2000 Insulin (Siemens Healthcare Diagnos-
tics, USA). Insulin resistance index (HOMA-IR) was cal-
culated (HOMA-IR  =  fasting insulin (mU/l)  ×  fasting 
glucose (mmol/l)/22.5), and oral glucose tolerance test 
(OGTT) with 75  g of glucose was performed according 
to World Health Organization (WHO) procedures (in 
groups DC and D).
GLUT4 expression measurements
GLUT4 expression measurements were performed using 
flow cytometry method [25]. Mononuclear cells were iso-
lated from blood samples on Gradisol L (fluid density of 
1.077 g/L, AQUA-MEDICA) and washed twice in 0.9 % 
NaCl. To mark the population of cells that do present 
GLUT4 protein expression monoclonal antibody (MoAb) 
anti-GLUT4 was used together with single color, indi-
rect immunofluorescence technique. Per single staining 
process the sample of 106 mononuclear cells was taken. 
Cells were incubated for 30 min with 2 µL of anti-GLUT4 
antibody in an ice bath of 4  °C and next washed with 
phosphate-buffered solution (PBS) with 0,01  % sodium 
azide (NaN3). The cells were next incubated for 20 min 
(ice bath, temp. 4 °C) with 10 µL of secondary, non-spe-
cific antibody binding to the immunoglobulin fragment 
F(ab’)2 and conjugated with fluorochrome-fluorescein 
isothiocyanate (FITC). Later the mononuclear (MNC) 
cells were washed again with PBS with 0.01 % NaN3 and 
suspended in 500  µL of FACS flow (Becton–Dickinson; 
USA). For data acquisition and analysis the Facs Calibur 
flow cytometer (Becton–Dickinson; USA) with Cell-
Quest software (Becton–Dickinson; USA) was used. The 
results were given as the percentage of cells presenting 
the expression of the investigated protein.
Phenotyping NK cells
Immunofluorescent phenotyping of NK (CD16+) and 
cytotoxic T cells (CD3+CD56+) in peripheral blood 
lymphocytes was performed using specific murine 
anti-human CD3/CD56  +  CD16 FITC-PE-conjugated 
monoclonal antibodies (Simultest, Becton–Dickinson; 
USA). Fluorescence analysis was performed using FACS 
Calibur flow cytometer and the Cellquest program. 
Lymphocytes T (CD3+) cells were identified with strong 
green fluorescence, NK cells (CD16+) with red fluores-
cence and cytotoxic lymphocytes (CD3+CD56+) were 
identified with green and red fluorescence. These studies 
were conducted at the Department of Nuclear Medicine.
Statistical methods
The data were presented as a mean and standard devia-
tion. Quantitative parameters were compared using the 
Aspin-Welch test with a marginal level of statistical sig-
nificance equaling P = 0.01. Variations in glucose uptake 
in peripheral blood lymphocytes were analyzed with 
Student’s test. Multiple factor regression was performed 
to analyze correlations of NK cells number and GLUT4 
expression with all studied clinical parameters.
Results
The characteristics of the studied groups are shown in 
Table  1. The duration of diabetes in D group was simi-
lar (statistically insignificant) to its duration in DC group. 
The studied groups did not differ in a statistically signifi-
cant manner in terms of number, gender, age, BMI and 
WHR. We noticed significant differences in biochemi-
cal parameters between patients in DC and D groups 
in comparison with the control group. In patients in D 
group we observed a significantly higher level of FPG 
(7.24 vs 5.34 mmol/L, P < 0.01) and HbA1c (7.23 vs 5.4 %, 
P < 0.01) in comparison to the control group, as well as 
significantly higher levels of insulin resistance—HOMA-
IR: 4.46 vs 1.89 and fasting insulin concentrations: 14.24 
vs 7.79 mU/L, respectively (P < 0.01).
In patients in DC group, the mean FPG levels (7.52 
vs 5.34  mmol/L, P  <  0.01) and HbA1c (7.27 vs 5.4  %, 
P  <  0.01) were significantly higher than observed in 
the control group, but did not differ significantly with 
respect to D group. In addition, patients in DC group 
were characterized by the highest mean fasting insulin 
(21.65 mU/L) and the highest value of HOMA-IR (6.96) 
when compared with different groups of patients, and 
the differences were statistically significant (P < 0.01) In 
patients in C group, the mean values of the tested bio-
chemical parameters were significantly lower than in 
patients in D group and also in the DC group. This group 
did not show statistically significant differences relating 
the control group (Table 1).
Subjects in DC group differed significantly from those 
in D group in terms of diabetic therapy. Metformin was 
the predominant anti-diabetic drug in D group, as it was 
used in 17/20 patients (85 %). Sulfonylureas were used in 
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4/20 patients (20 %), acarbose in 3/20 (15 %) and incre-
tin mimetics in 2/20 patients (10  %). The vast majority 
of patients in DC group (15/19–79 %) was treated with a 
sulfonylurea, 9/19 (47 %) with metformin, 2/19 (10.5 %) 
with acarbose and 1/19 (5 %) with incretin mimetics.
GLUT4 expression
Patients in D group were characterized by the highest 
GLUT4 expression on the surface of NK cells in compari-
son with others groups (21.35 ± 7.2 %), and these differ-
ences were statistically significant (P  <  0.01). This study 
also showed that the mean values of GLUT4 expression 
in C group were similar to the mean GLUT4 expression in 
DC group (1.4 ± 0.4 % vs 1.5 ± 1.0 %; respectively). These 
values were statistically significantly lower than in control 
group (12.6 ± 2.9 %; P = 0.01) (Fig. 1). We have found no 
simple correlations between GLUT4 expression and other 
clinical factors such as age, BMI, WHR, FPG, HOMA, 
Insulin and HbA1c level in the studied groups (Table 2).
Number of NK cells
In D group we noticed a significantly increased num-
ber of NK cells in comparison to the control group 
(14.08 ± 5.7 % vs 9.48 ± 4.7 %, P < 0.01). In patients in 
DC group we observed, that NK cell count was sig-
nificantly higher in comparison with the control group 
(20.15 ± 6.6 % vs 9.48 ± 4.7 %, P < 0.01). In patients with 
CC without carbohydrate metabolism disturbances simi-
lar number of NK cells in relation to the control group 
was noted (9.21 ± 3.6 %, ns) (Fig. 2).
Patients in DC group were characterized by a signifi-
cantly higher NK cell count compared to those from D 
group (P < 0.01), as well as to individuals from C group 
(P < 0.01). In D group, a higher number of NK cells was 
observed when compared with the C group (P  <  0.01) 
(Fig. 2). We have found no correlations between NK cells 
number and other clinical factors in the studied groups 
(Table. 3).
Discussion
The growing incidence of type 2 diabetes as well as neo-
plasms constitutes a major socio-economic problem. 
The early identification of patients from the groups of 
increased risk of these diseases allows the introduction of 
preventive countermeasures what is especially important 
in Polish population with the high prevalence of type 2 
diabetes and colon cancer.
This study was focused on determination of the impact 
of type 2 diabetes as well as colon cancer on the number of 
NK cells and expression of GLUT4 on the surface of these 
cells. We demonstrated, that in patients with type 2 diabe-
tes but without colon cancer GLUT4 expression was higher 
than in control group but also significantly higher than 
in patients with type 2 diabetes and concomitant colon 
cancer. We also noticed, that the mean values of GLUT4 
expression in patients with normal glucose tolerance and 
colon cancer were similar to the mean GLUT4 expression 
in patients with colon cancer and type 2 diabetes.
GLUT 4 is present on the surface of leukocytes and the 
regulation of this expression is associated with the func-
tions of particular cells [25, 26]. GLUT4 can facilitate glu-
cose transport, glucosamine and dehydroascorbic acid and 
its expression is not only restricted to leukocytes but also 
is presented in tissue with a marked insulin dependent 
glucose transport like, heart, adipose tissue, and skeletal 
muscle [27]. When insulin binds to its receptor, GLUT4 
Table 1 Characteristics of the study groups (x ± SD)
BMI body mass index, WHR waist/hip ratio, SBP systolic blood pressure, DBP 
diastolic blood pressure, FPG fasting plasma glucose
Comparing the parameters of various study groups was made relative to the 
control group; * P < 0.01
a HOMA-IR index was calculated on the basis of HOMA formula = fasting insulin 
(mU/l) × fasting glucose (mmol/l)/22.5
Parameter Control group D C DC
No. pts. 20 20 19 19
Sex, M/F 10/10 10/10 10/9 9/10
Age, years 55.5 ± 8.1 55.4 ± 7.8 56.4 ± 8.0 56.0 ± 8.0
BMI, kg/m2 26.6 ± 2.9 27.0 ± 5.1 25.9 ± 3.3 26.3 ± 2.9
WHR, m/m 0.88 ± 0.08 0.89 ± 0.08 0.88 ± 0.09 0.87 ± 0.08
T2D, years − 6.5 ± 3.1 − 6.7 ± 3.1
FPG, mmol/l 5.3 ± 0.7 7.2 ± 0.8* 5.5 ± 0.8 7.5 ± 0.9*
HbA1c,  % 5.4 ± 0.8 7.2 ± 0.7* 5.5 ± 0.7 7.3 ± 0.9*
Insulin, mU/l 7.8 ± 3.5 14.2 ± 1.6* 8.2 ± 4.6 21.7 ± 8.1*
HOMA‑IRa 1.89 ± 1.05 4.46 ± 1.8* 1.99 ± 1.2 6.96 ± 2.8*
12,6 ± 2,9
21,35 ± 7,2








Control D C DC
GLUT4%
Fig. 1 Comparison of the quantitative expression of GLUT4 on the 
surface of NK cells in the control group, patients with diabetes type 
2 (D), colon cancer (C) and patients with both D and C (DC). The differ‑
ences between study groups are statistically significant (P < 0.01)
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is rapidly translocated to plasma membrane, increasing 
glucose uptake in the cell. Because muscle and fat tissues 
comprise a large fraction of the body mass, GLUT4 plays 
a central role in glucose metabolism and represents 90 % 
of GLUTs [17]. Moreover, GLUT4 expression is regulated 
in a tissue-specific manner and magnitude of GLUT4 
expression is controlled by different factors, such as diet, 
exercise and insulin [28]. Finally, GLUT4 displays a con-
nection with cancer, as a transporter is transcriptionally 
repressed by p53, a tumor suppressor protein important 
for cell cycle control and apoptosis, processes that are 
usually altered in cancer [18].
Many cancers display high rates of glucose uptake and 
one of the explanation is the overexpression of GLUT 
proteins. GLUTs overexpression has been observed in 
many cancers and expression levels were inversely cor-
related with prognosis [16]. Elevated levels of glucose 
uptake are induced by activated ras or src oncogenes 
which are key elements in the transduction of multi-
ple signaling pathways [29]. In CC cell lines, mutations 
in KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog) or BRAF (vraf murine sarcoma viral oncogene 
homolog B1) genes, are able to trigger an overexpression 
of GLUT1 and an increase of the glucose uptake. Fur-
thermore, the exposition of CC cell lines to low levels of 
glucose contributes to the development of mutations in 
KRAS, which give rise to the upregulation of GLUT1 and 
to an increase in glucose uptake [30].
Deregulated GLUT4 expression has been described in 
RCC (renal cell carcinoma). The expression of different 
GLUTs is altered in a histological subtype-specific man-
ner. In conventional clear cell RCC, GLUT1 expression is 
increased, while the expression of GLUT4, GLUT9, and 
GLUT12 decreases versus the healthy kidney. In chromo-
phobe RCC, GLUT4 expression is increased, while the 
expression of GLUT2 and GLUT5 is decreased [31].
GLUTs expression was also studied in a CC biopsies. 
These study revealed that GLUT1 expression was asso-
ciated with tumor progression and poorer prognosis 
[32]. The expression of GLUT1 and Ki-67, as cell pro-
liferation marker, were also analyzed in different zones 
of CC samples [33]. In central and superficial part of 
tumors, no significant differences were detected between 
GLUT1 expression, Ki-67 expression, and clinic-patho-
logical parameters. However, in the deepest invasive site, 
GLUT1 expression was associated with Ki-67 labeling 
index. In addition, in patients who underwent curative 
surgery, the GLUT1 expression at the deepest invasive 
site was significantly associated with poorer prognosis. 
Table 2 The correlations between GLUT4 expression and other clinical factors in study groups
NS statistically not significant (P < 0.05), r Pearson correlation, D diabetes mellitus type 2, C colon cancer, DC diabetes mellitus type 2 and colon cancer
Variable Control D C DC
r P r P r P r P



































































Control D C DC
NK number%
Fig. 2 Comparison of the percentage of NK cells in the control 
group, patients with diabetes type 2 (D), colon cancer (C) and patients 
with both D and C (DC). The differences between study groups are 
statistically significant (P < 0.01)
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Therefore, GLUT1 expression may be used as predictor 
of poor prognosis in advanced CC.
In our study we demonstrated significant lower-
ing of GLUT4 expression on NK cells in patients with 
colon cancer not only in group with coexisting type 2 
diabetes but also in subjects with normal glucose toler-
ance. These findings indicate that disturbances of cel-
lular glucose transport may be present in patients with 
normal glucose homeostasis and cancer. It must be 
pointed, that there is the relationship between GLUT4 
expression on NK cells surface and their functions 
which is confirmed by low GLUT4 expression on NK 
cells observed in patients with colon cancer and asso-
ciated with impaired NK cells cytotoxicity in these 
patients [23]. The higher GLUT4 expression on NK 
cells in patients with type 2 diabetes but without cancer 
is probably associated with compensative mechanism, 
which is responsible for proper glucose transport to 
these cells despite insulin resistance and hyperglyce-
mia. Similar findings, confirm higher GLUT4 expres-
sion on NK cells with decreased cytotoxic activity in 
patients with type 2 diabetes, were showed in other our 
studies [12, 34].
Our findings confirm hypothesis, that pointed above 
compensative mechanism is significantly impaired in 
case with coexisting cancer, because in diabetic patients 
with colon cancer we observed NK cells activity about 
fourfold lower when compared with diabetic patients 
without colon cancer [25] and followed by low GLUT4 
expression that we demonstrated in this study. These 
results are hints suggesting that monitoring of GLUT4 
expression on NK cells in patients with type 2 diabetes, 
which indirectly reflects cytotoxic activity of these cells, 
may be helpful in proper identification of people with 
increased risk of cancer.
This study was also focused on determining the impact 
of type 2 diabetes and colon cancer on the number of 
NK cells. Our study showed that the NK cell count is 
increased in subjects with type 2 diabetes without cancer 
as well as in subjects with coexisting type 2 diabetes and 
colon cancer when compared to healthy subjects. Simul-
taneously, we observed no statistically significant differ-
ence concerning the number of NK cells in patients with 
colon cancer and normal glucose tolerance in compari-
son to the control group. In this study, changes in num-
ber of NK cells in the patients with type 2 diabetes and a 
coexisting colon cancer were accompanied by increased 
levels of fasting insulin and high HOMA-IR value. We 
can therefore conclude that there is a correlation between 
the abnormal number of NK cells and the grade of insulin 
resistance. These alterations are observed in people with 
type 2 diabetes whose impaired immune system may lead 
to an impairment in antitumor defense, and are probably 
related to hyperinsulinemia.
In our cohort patients with type 2 diabetes but with-
out colon cancer differed from those with type 2 diabetes 
and colon cancer in terms of applied antidiabetic therapy. 
Metformin was predominantly used in patients with type 
2 and without cancer, while the vast majority of patients 
with type 2 diabetes and coexisting colon cancer was 
treated with sulfonylurea drugs. It was shown, that met-
formin intake reduces the risk of colon cancer [35] and 
the protective effect of metformin appears to result from 
its inhibitory effect on intracellular transduction mecha-
nisms stimulated by the activation of insulin receptor/
insulin like growth factor (IGF) axis [36].On the contrary, 
Table 3 The correlations between NK cells numbers and other clinical factors in study groups
NS statistically not significant (P < 0.05), r Pearson correlation, D diabetes mellitus type 2, C colon cancer, DC diabetes mellitus type 2 and colon cancer
Variable Control D C DC
r P r P r P r P
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treating of diabetes with drugs stimulating insulin release 
may increase the risk of cancer.
Proper identification of diabetic patients with increased 
risk of colon cancer is essential in order to implement ade-
quate preventing procedures. According to guidelines of 
the Polish Society of Gastroenterology, full colonoscopy is 
suggested to be the preferred screening method of colon 
cancer screening in Poland and should be performed once 
every 10 years in people aged over 50 years and in subjects 
with an increased risk of this cancer (genetic factors, posi-
tive family history). None of scientific societies in Poland 
considers patients with type 2 diabetes as subjects with 
a higher risk of developing colon cancer and potential 
candidates to routine colonoscopy, unfortunately. It was 
documented, that screening colonoscopy results in signif-
icant decline in the incidence of colon cancer and mortal-
ity [37–39] but in many cases the diagnosis is established 
too late. Therefore, there has been a discussion concern-
ing the best screening methods for diagnosis of colon can-
cer. It seems that there is a need to pay more attention to 
the high incidence of this cancer among type 2 diabetic 
patients in order to improve diagnostic and therapeutic 
methods in this particular group of patients.
Nowadays NK cell-based therapeutic strategies and 
selective glucose transporter-directed therapies comprise 
promising option that may improve chance of successful 
anti-tumor treatment not only in colon cancer [40], but 
in various types of neoplastic disorders [41–44]. Moreo-
ver, the pharmacological inhibition of co-transporters 
SGLT2 is safe and efficient in treating type 2 diabetes. 
SGLT2 inhibitors (gliflozins) are medications available 
in many countries and used in medical practice [45]. It 
has been recently revealed that one of SGLT2 inhibi-
tors—empagliflozin, when added to standard treatment, 
reduces the risk of cardiovascular events and death from 
any cause [46]. It may be supposed that GLUT proteins 
will be the next target for new antidiabetic drugs.
Conclusions
Impaired GLUT4 expression and altered number of NK 
cells are probably associated with increased incidence 
of colon cancer in patients with type 2 diabetes. Further 
studies in this field are necessary to explain the patho-
physiological mechanisms that lead to the frequent inci-
dence of colon cancer in subjects with type 2 diabetes. 
Patients with diabetes are at risk of developing colorec-
tal cancer, they must undergo screening tests. Diabetic 
patients education on this problem is also essential.
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